-
1 Comment
Mayne Pharma Group Limited is currently in a long term downtrend where the price is trading 9.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
Mayne Pharma Group Limited's total revenue sank by 0.0% to $114M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-9M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.3% to $20M since the same quarter in the previous year.
Based on the above factors, Mayne Pharma Group Limited gets an overall score of 1/5.
Industry | Drug Manufacturers - General |
---|---|
Exchange | F |
CurrencyCode | EUR |
ISIN | AU000000MYX0 |
Sector | Healthcare |
Beta | 1.27 |
---|---|
Market Cap | 315M |
PE Ratio | None |
Target Price | None |
Dividend Yield | None |
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women's Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HG6.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025